ArticleEuropean journal of nuclear medicine and molecular imaging2021
Clinical translation and implementation of optical imaging agents for precision image-guided cancer surgery.
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Concept for Preoperative and Intraoperative Molecular Imaging and Detection for Assessing Extent of Disease of Solid Tumors.Oncology reviews · 2024Pooled it
- Endoglin/CD105-Based Imaging of Cancer and Cardiovascular Diseases: A Systematic Review.International journal of molecular sciences · 2021Pooled it
- Bridging preclinical and clinical fluorescence-guided surgery with advanced cancer vision goggles.Npj imaging · 2026Article
- Standardizing clinical trials in near-infrared fluorescence imaging: a workflow and regulatory framework proposal.Npj imaging · 2026Review
- Multidimensional lung imaging: integrated preclinical platforms enabling the identification of translational biomarkers for pulmonary research.Respiratory research · 2026Review
- From Imaging to Impact: A Multi-Disciplinary T32 Program Framework and Initial Insights for Training in Image-Guided Cancer Therapy [Advance Publication].Advances in cancer education and quality improvement · 2025Article
- Advances in Optical Contrast Agents for Medical Imaging: Fluorescent Probes and Molecular Imaging.Journal of imaging · 2025Review
- Review
- Normalization of Time-Intensity Curves for Quantification of Foot Perfusion Using Near-Infrared Fluorescence Imaging With Indocyanine Green.Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists · 2023Article
- Fluorescence-guided surgery: comprehensive review.BJS open · 2023Review
- Intraoperative fluorescence molecular imaging accelerates the coming of precision surgery in China.European journal of nuclear medicine and molecular imaging · 2022Review
- Optical magnetic multimodality imaging of plectin-1-targeted imaging agent for the precise detection of orthotopic pancreatic ductal adenocarcinoma in mice.EBioMedicine · 2022Article
- Standardization and implementation of fluorescence molecular endoscopy in the clinic.Journal of biomedical optics · 2022Article
- Fundamentals and developments in fluorescence-guided cancer surgery.Nature reviews. Clinical oncology · 2022Review
- Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionThe field of tumor-specific fluorescence-guided surgery has seen a significant increase in the development of novel tumor-targeted imaging agents. Studying patient benefit using intraoperative fluorescence-guided imaging for cancer surgery is the final step needed for implementation in standard treatment protocols. Translation into phase III clinical trials can be challenging and time consuming. Recent studies have helped to identify certain waypoints in this transition phase between studying imaging agent efficacy (phase I-II) and proving patient benefit (phase III). TRIAL INITIATION: Performing these trials outside centers of expertise, thus involving motivated clinicians, training them, and providing feedback on data quality, increases the translatability of imaging agents and the surgical technique. Furthermore, timely formation of a trial team which oversees the translational process is vital. They are responsible for establishing an imaging framework (camera system, imaging protocol, surgical workflow) and clinical framework (disease stage, procedure type, clinical research question) in which the trial is executed. Providing participating clinicians with well-defined protocols with the aim to answer clinically relevant research questions within the context of care is the pinnacle in gathering reliable trial data. OUTLOOK: If all these aspects are taken into consideration, tumor-specific fluorescence-guided surgery is expected be of significant value when integrated into the diagnostic work-up, surgical procedure, and follow-up of cancer patients. It is only by involving and collaborating with all stakeholders involved in this process that successful clinical translation can occur.
aimHere, we discuss the challenges faced during this important translational phase and present potential solutions to enable final clinical translation and implementation of imaging agents for image-guided cancer surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.